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Abstract
Background: Mediterranean societies, with diets rich in vitamin E isoforms, have a lower risk for colon cancer than those of
northern Europe and the Americas. Vitamin E rich diets may neutralize free radicals generated by fecal bacteria in the gut and
prevent DNA damage, but signal transduction activities can occur independent of the antioxidant function. The term vitamin E
represents eight structurally related compounds, each differing in their potency and mechanisms of chemoprevention. The RRR-
γ-tocopherol isoform is found primarily in the US diet, while RRR-α-tocopherol is highest in the plasma.
Methods: The effectiveness of RRR-α- and RRR-γ-tocopherol at inhibiting cell growth and inducing apoptosis in colon cancer
cell lines with varying molecular characteristics (SW480, HCT-15, HCT-116 and HT-29) and primary colon cells (CCD-
112CoN, nontransformed normal phenotype) was studied. Colon cells were treated with and without RRR-α- or RRR-γ-
tocopherol using varying tocopherol concentrations and time intervals. Cell proliferation and apoptosis were measured using
the trypan blue assay, annexin V staining, DNA laddering and caspase activation.
Results: Treatment with RRR-γ-tocopherol resulted in significant cell death for all cancer cell lines tested, while RRR-α-
tocopherol did not. Further, RRR-γ-tocopherol treatment showed no cytotoxicity to normal colon cells CCD-112CoN at the
highest concentration and time point tested. RRR-γ-tocopherol treatment resulted in cleavage of PARP, caspase 3, 7, and 8, but
not caspase 9. Differences in the percentage cell death and apoptosis were observed in different cell lines suggesting that
molecular differences in these cell lines may influence the ability of RRR-γ-tocopherol to induce cell death.
Conclusion: This is the first study to demonstrate that multiple colon cancer cell lines containing varying genetic alterations
will under go growth reduction and apoptosis in the presence of RRR-γ-tocopherol without damage to normal colon cells. The
amount growth reduction was dependent upon the molecular signatures of the cell lines. Since RRR-γ-tocopherol is effective at
inhibition of cell proliferation at both physiological and pharmacological concentrations dietary RRR-γ-tocopherol may be
chemopreventive, while pharmacological concentrations of RRR-γ-tocopherol may aid chemotherapy without toxic effects to
normal cells demonstrated by most chemotherapeutic agents.
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Background
Differences in the incidence of colorectal cancer through-
out the world suggest that diet has a role in colorectal car-
cinogenesis [1]. Mediterranean diets, rich in vitamin E
isoforms, are associated with a lower incidence of colon
cancer [2,3]. Vitamin E refers to any of four tocopherols or
tocotrienols (α, β, δ, and γ) isoforms. All of the tocopherol
isoforms found in nature are the RRR-forms since all three
chiral carbons on the side chain attached to the chroman
head group have the "R-" configuration rather then the "S-
" configuration. Synthetic vitamin E (typically found in
dietary supplements) almost always refers to all-rac-
alpha-tocopherol which is a racemic mixture containing
eight stereo isomers, one eighth of which is the biologi-
cally active RRR-isoform. The isoform found in highest
concentration in the serum is the RRR-α-tocopherol. The
primary form of vitamin E found in the North American
diet is RRR-γ-tocopherol, which is present at levels 2–4
times higher than that of RRR-α-tocopherol [4].
While most clinical studies with vitamin E have used all-
rac-α-tocopherol, recent studies show that RRR-γ-toco-
pherol also may play a unique role in preventing colon
cancer [5]. Epidemiological evidence shows that RRR-γ-
tocopherol levels in plasma correlate with a reduced risk
for both colon and prostate cancer [6-8]. Animal studies
measuring direct end-points of cancer (i.e., survival stud-
ies, tumor reduction, tumor prevention) with RRR-γ-toco-
pherol are lacking. Vitamin E was demonstrated a
chemopreventive in animal models of chemically induced
colon cancer [9], but these studies tested only α-tocophe-
rol or α-tocopherol acetate (RRR- or all-rac- not specified).
Animal studies measuring the potential chemopreventive
mechanisms of RRR-γ-tocopherol have used surrogate
biomarkers of carcinogenesis. For example, RRR-γ-toco-
pherol can suppress the expression of ras p-21 in rat
colonocytes in vivo [10]. Using Wistar rats, Jiang has dem-
onstrated that RRR-γ-tocopherol, but not α-tocopherol
(RRR- or all-rac- not specified) decreases the proinflam-
matory eicosanoid PGE2 (which is known to play a role in
the progression of colorectal cancer through inflamma-
tion). Further, hemodialysis patients administered RRR-γ-
enriched tocopherols showed a consistently lower level of
C-reactive protein (a biomarker of inflammation) while
the administration of α-enriched tocopherols (RRR- or
all-rac- not specified) did not [11].
Cooney et al. found that RRR-γ-tocopherol was a much
more potent inhibitor of neoplastic transformation in 3-
methycholanthrene-treated C3H/H10T/1/2 murine
fibroblasts than α-tocopherol (RRR- or all-rac- not speci-
fied) [12]. In addition, RRR-γ-tocopherol is a potent
inhibitor of COX-2 activity and inhibits human cancer
cell cycle progression and cell proliferation by down-reg-
ulation of cyclins [13,14]. Stone et al. have found that
RRR-γ-tocopherol is taken up by RAW 264.7 macrophages
to a much greater extent than RRR-α-tocopherol [15].
Vitamin E isoforms (and metabolites) have had varying
effectiveness at inhibiting cell growth and inducing apop-
tosis. RRR-γ-Tocopherol is superior to all-rac-α-tocophe-
rol at cell growth inhibition in vitro in human prostate
cancer cells [16]. Vitamin E succinate (VES) and tocot-
rienols demonstrate potent apoptotic inducing properties
[17]. Zu et al. [18] have shown differential synergistic
effects of selenium with vitamin E isoforms on cell growth
and apoptosis in PC-3 human prostate cancer cells. VES
was the most effective form tested and synergizes with
selenium, while RRR-α-tocopherol and RRR-α-tocopheryl
acetate were weaker in their effects on suppressing growth
and inducing apoptosis in PC-3 prostate cancer cells. α-
Tocopherol (RRR or all-rac not specified) is a poor inducer
of apoptosis in the colon cancer xenograft nude mouse
model, while the synthetic form, α-tocopheryl succinate
(a redox inactive analogue of vitamin E) is a strong
inducer of apoptosis [19]. In addition, carboxyethyl
hydroxychromans (CEHC) metabolites of γ-tocopherol
are powerful inducers of apoptosis and inhibit cell growth
and down regulate cyclin expression in PC-3 prostate can-
cer cell lines [20]. The performance of vitamin E deriva-
tives and analogues with regard to apoptosis also vary
among tissue types. VES and a vitamin E analogue,
2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chro-
man-6-yloxy acetic acid (α-TEA) can induce human
breast, prostate, colon, lung, cervical, and endometrial
tumor cells, but the apoptotic-inducing effects of α-TEA
are greater in human ovarian and cervical cancer cells
[21]. To date, no study has compared the anti-prolifera-
tive and apoptotic effects of α- and γ-tocopherol on colon
cancer cell lines with differences in molecular features.
Gysin et al. demonstrated the inhibition of cell prolifera-
tion by RRR-γ-tocopherol treatment at 25 µM on CaCo-2
(colon carcinoma), DU-145 and LNCap (prostate carci-
noma) and SaOs-2 (osteosarcoma) cells, but demon-
strated no apoptosis in any of the cell lines tested.
In this study, we compared the anti-proliferative and
apoptotic effects of RRR-α-tocopherol and RRR-γ-toco-
pherol in four colon cancer cell lines with varying molec-
ular characteristics, SW480 (APC, type I truncation and
COX-2 deficient), HCT-15 (COX-2 deficient), HCT-116
(APC, wild-type and COX-2 inducible), and HT-29 (APC,
type II truncation and COX-2 constitutive expression) and
normal untransformed colon cells (CCD-12CoN). Prolif-
eration studies demonstrated that RRR-γ-tocopherol is
able to inhibit proliferation and cause cell death in all
four cancer cell lines, but not in the normal cells. In the
colon cancer cell lines tested for apoptosis, we have
shown that RRR-γ-tocopherol activates cleavage of PARP
and caspase 3, 7 and 8, but not caspase 9. Dietary RRR-γ-BMC Cancer 2006, 6:13 http://www.biomedcentral.com/1471-2407/6/13
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tocopherol may be an effective colon cancer preventive
agent while pharmacological concentrations of RRR-γ-
tocopherol may be useful as an adjuvant chemotherapy
agent resulting lower dose of agents that are cytotoxic to
normal cells.
Methods
Chemicals
α-Tocopherol (Eastman Chemical, Kingsport, TN, 99%
pure RRR-α-tocopherol), γ-tocopherol (Tama Biochemi-
cal, Tokyo, Japan, 97% pure RRR-γ-tocopherol), troglita-
zone (BioMol Research Lab, Plymouth Meeting, PA), 15-
deoxy∆12,14-PGJ2  (BioMol Research Lab, Plymouth
Meeting, PA), bovine serum albumin (Gibco BRL, Gaith-
ersburg, MD), proteinase K (Sigma Chemical, St. Louis,
MO), RNAse A (Sigma Chemical, St. Louis, MO), and
camptothecin (Sigma Chemical, St. Louis, MO) were
obtained from the indicated sources.
Cell culture
The colon cancer cell lines SW480 (RPMI 1640), HCT-116
(McCoy's), HT-29 (Dulbecco's Modified Eagle Medium),
and HCT-15 (RPMI 1640) were purchased from American
Type Culture Collection, ATCC (Manassas, VA) and
grown in the indicated media supplemented with 10%
FBS and 50 IU penicillin/streptomycin in a humidified
atmosphere of 5% CO2 at 37°C. The CCD-112CoN (nor-
mal primary cells, nontransformed phenotype) were
grown in a humidified atmosphere of 5% CO2 at 37°C
with Dulbecco's Modified Eagle's and supplemented with
10% FBS.
Enrichment of tocopherol into tissue culture medium
Prior to treatment, the cell culture medium was enriched
with tocopherol by adding the appropriate amount of
tocopherol in ethanol, followed by five volumes of bovine
serum albumin (BSA). The BSA/tocopherol mixture was
vortexed and added to appropriate culture medium. In the
vehicle-treated cells, the tocopherol was omitted from the
BSA/ethanol mixture which was added to the appropriate
culture medium supplemented with 10% FBS.
Percent dead assay
Percent cell death was measured by using the Live-Dead
Assay according to the manufacturer's instructions
(Molecular Probes, Eugene, OR) with a Gemini XS fluor-
imeter (Molecular Devices, Sunnyvale, CA). The percent-
age of cell death was calculated by measuring the
fluorescence intensity of the ethidium bromide
homodimer (EthD-1) that is excluded from live cells, but
enters the cells with damaged membranes and undergoes
a fluorescence enhancement upon binding to nucleic
acids in dead cells (λex = 530 nm and λem = 645 nm). Con-
trol samples for percent dead calculations were verified for
viability before and after plating using the trypan blue
exclusion assay. EthD-1 dye and cell concentrations were
optimized according to manufacturers' instructions.
SW480 cells were seeded at a density of 5 × 104 cells/well
while HCT-116 cells were plated at a density of 2 × 104
cells/well in 96-well plates for 24 hours before treatment.
Vitamin E-enriched PBS (previously described) was added
at 25, 50, 100, 150 and 200 µM concentrations. Cells were
treated for five hours.
Cell viability and cell death analysis
SW480, HT-29, HCT-116 and HCT-15 cells were seeded at
1.5 × 105 cells/well in 12 well plates 24 hours prior to
tocopherol treatment for time intervals to 72 hours. Toco-
pherol-enriched media was added to a concentration up
to 100 µM tocopherol. This concentration was selected
after performing Live-Dead Assays (Molecular Probes)
and determining that it was the lowest concentration
where cell death was mediated by α-tocopherol. We
selected this concentration to determine if α-tocopherol
could induce apoptosis. Cells were removed from flasks
by trypsinization at indicated times and counted with a
hemocytometer using trypan blue staining and the Beck-
man Coulter Z2 cell counter. The cells were assayed by
trypan blue exclusion stain as described above. At lower
tocopherol concentrations and incubation times the cells
were seeded at 1 × 104 cells/well. Tocopherol enriched
media was added to the appropriate concentration at the
zero time interval and was replenished every 72 hours.
Cell viability was assayed hemocytometer cell counting
with trypan blue dye. Troglitazone, 15-deoxy ∆12,14-
PGJ2, and camptothecin are capable of inducing cell death
and apoptosis in colon cancer cells and were used as pos-
itive controls for cell death and apoptosis. Cell viability
was measured by live cell counts as a function of time and
compared to the vehicle, while cell death was measured as
the percentage of dead cells at each time point measured.
Intracellular analysis of vitamin E by HPLC analysis
The tocopherol content of the treated cell lysates was
measured using HPLC analysis with highly sensitive elec-
trochemical detection as previously described [22]. The
response factors of tocopherols relative to tocol (an inter-
nal standard) were determined in triplicate. The concen-
trations of RRR-α-tocopherol and RRR-γ-tocopherol were
measured using a Spectronic Genesys 5 spectrophotome-
ter and published extinction coefficients [23].
Apoptosis assays
Annexin V and propidium iodide (PI) double staining assay
HCT-116 and SW480 cells were plated in 100 × 20 mm
plates at cell densities between 3 × 106 and 5 × 106 cells/
plate. HCT-116 cells and SW480 cells were treated as
described in the trypan blue staining assays. After treat-
ment, cells were removed from the plate with trypsin and
analyzed for phosphatidylserine externalization by anBMC Cancer 2006, 6:13 http://www.biomedcentral.com/1471-2407/6/13
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SW480, HCT-116, and HT-29 cells were treated for 5 hours with varying concentrations of tocopherol or the PPAR γ ligand,  troglitazone (positive control) Figure 1
SW480, HCT-116, and HT-29 cells were treated for 5 hours with varying concentrations of tocopherol or the PPAR γ ligand, 
troglitazone (positive control). The percent of dead cells for SW480 cells (A), HCT-116 cells (B) or HT-29(C) was measured 
using the Live-Dead assay (Molecular Probes, CA). (Data are representative of three independent trials performed in triplicate. 
*p < 0.05 vs. vehicle at corresponding concentration.)
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annexin V and propidium iodide apoptosis kit (Oncogene
Research Products, San Diego, CA) according to the man-
ufacturers' instructions using a Becton Dickson FACS Cal-
ibur Flow Cytometer (Becton Dickson, San Diego, CA).
Apoptotic cells were counted by flow cytometry and the
resulting data analyzed using WinMDI freeware.
DNA laddering assay
DNA fragmentation was measured by gel electrophoresis
by the standard published procedures. In brief, the cells
were plated at a density of 5 × 106 cells/plate and treated
with 100 µM tocopherol-enriched, vehicle-enriched
media or 10 µM camptothecin (positive control) for 48
hours. A concentration of 1 × 106 cells/mL were pelleted
and resuspended in lysis buffer (50 mM Tris HCl, 10 mM
EDTA, 0.5% SDS). The cell lysates were treated with 20
mg/mL proteinase K and incubated at 55°C for 1 hour fol-
lowed by addition of 0.5 mg/mL RNAse A and heated to
70°C for 5 minutes. DNA was precipitated with isopropa-
nol, mixed with loading dye (10 mM EDTA, pH 8.0, 40 %
sucrose, 0.25 % bromophenol blue) and analyzed on a
2% agarose gel containing 0.5 µg/mL ethidium bromide.
Gel images were captured using an Alpha Innotech digital
camera equipped with a transilluminator and Alpha Ease
5.5 software (Alpha Innotech Corporation, San Leandro,
CA).
PARP and caspase cleavage by western blot analysis
The protein concentration of the cells lysates was deter-
mined by the BCA protein assay (Pierce Biotechnology,
Rockford, IL). Total protein was separated by electro-
phoresis on a 12% SDS polyacrylamide gel and electro
transferred onto Hybond-ECL nitrocellulose membrane
using an X cell II Mini Cell Blot module (San Diego, CA).
Blotted membranes were incubated with the primary anti-
bodies indicated as follows: caspase 3, 7, 8 and 9 (Cell Sig-
naling Technology, Beverly, MA) and probed with
horseradish peroxidase conjugated secondary antibody
(Cell Signaling Technology, Beverly, MA). The signal was
revealed on hyperfilm using the ECL Western blotting
detection reagents 1 and 2 (1 mL each) detection system
(Amersham Biosciences, Arlington Heights, IL). To con-
trol for consistent loading, membranes were probed with
the β-actin antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) after stripping the blot with Restore solution
(Pierce Biotechnology, Rockford, IL) for 30 minutes at
37°C.
Statistics
Data is displayed as means with error bars representing
standard deviation (SD). One-way analysis of variance
(ANOVA) followed by Tukey's test was used to compare
the means of live cells in the cell proliferation assays and
percentage cell death. Probability levels (p-values) of <
0.05 indicate statistical significance. The values obtained
from annexin V staining and cell cycle data are measured
as a percentage of the 10,000 events in the analysis. The
apoptosis in the control cells are subtracted from the
treated samples. The percentage values represent an aver-
age percentage apoptotic cells over the control (set at 0%)
of two independent assays performed in duplicate.
Results
Effects of RRR-α- and RRR-γ-tocopherol treatment on cell 
death in human colon cancer cells
Using the Live-Dead Assay (Molecular Probes) cell death
was monitored with physiological and pharmacological
concentrations of Vitamin E after 5 hours of treatment
(Figure 1). The results varied among the cell lines, how-
ever RRR-γ-tocopherol demonstrated a concentration-
dependent increase in cell death over the vehicle in all cell
lines tested. RRR-α-tocopherol did not demonstrate sig-
nificant cell death over the vehicle at any concentration
tested in the HCT-116 and was only significant at 200 µM
in the HT-29 cells. The RRR-γ-tocopherol treatment
resulted in significant cell death above the vehicle-treated
cells in the SW480 and HCT-116 at all concentrations
tested (25 µM through 200 µM). For the HT-29 cell line,
RRR-γ-tocopherol at levels of 50 µM were effective at
inducing cell death. The RRR-α-tocopherol treatment
resulted in significant cell death at 100 µM in the SW480
and HCT-116 cell lines, while the HT-29 cells required
200 µM α-tocopherol to increase cell death above the con-
trol. One-way ANOVA and tukey's statistical analysis was
used to compare the dead cell means for each treatment to
that of the vehicle. Asterisks above the bars demonstrate
p-values less than 0.05 for cell mean comparison with the
vehicle treatment. Post-hoc analysis (Tukey's test)
revealed that RRR-γ-tocopherol was significantly better at
inducing cell death than RRR-α-tocopherol in SW480 (at
all concentrations tested) and HCT-116 cells (at concen-
trations higher than 50 µM).
Since our goal was to determine if both vitamin E iso-
forms (RRR-α- and RRR-γ-tocopherol) could induce apop-
tosis, a concentration was selected whereby cell death
could be obtained with both isoforms. When treated with
RRR-α-tocopherol, cells did not exhibit cell death at con-
centrations lower than 100 µM (Figure 1).
Effects of RRR-α- and RRR-γ-tocopherol treatment on cell 
proliferation in human colon cancer cells
Since cell death and cell proliferation are different proc-
esses, live cell counts were monitored over time in the four
colon cancer cell lines, SW480, HCT-116, HCT-15, and
HT-29 with 100 µM RRR-α- and RRR-γ-tocopherol treat-
ment (Figure 2A–D). This was designed to assess the
effects of the tocopherols on cell proliferation. In the
HCT-116 and HT-29 (COX-2 positive) cell lines, RRR-α-
tocopherol treatment resulted in a statistically significantBMC Cancer 2006, 6:13 http://www.biomedcentral.com/1471-2407/6/13
Page 6 of 14
(page number not for citation purposes)
Growth curves for SW480 cells (A) HCT-116 cells (B), HCT-15 cells (C), HT-29 (D) were plotted as average cell counts over  time after treatment with 100 µM tocopherol at 1, 2, and 3 days Figure 2
Growth curves for SW480 cells (A) HCT-116 cells (B), HCT-15 cells (C), HT-29 (D) were plotted as average cell counts over 
time after treatment with 100 µM tocopherol at 1, 2, and 3 days. and Live Cell Counts in CCD-112CoN cells following 100 µM 
tocopherol treatment at 72 hours (E). Values plotted are averages of three independent trials. Error bars represent standard 
deviation of the means. Positive controls used included (15 deoxy ∆ 12,14 PGJ2, troglitzone and camptothecin). (Data are rep-
resentative of three independent trials performed in triplicate. *p < 0.05 vs. vehicle at corresponding concentration.)
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decrease in cell proliferation, but the RRR-γ-tocopherol
treatment resulted in a more pronounced decrease in cell
proliferation compared with RRR-α-tocopherol. In fact,
RRR-γ-tocopherol was statistically different from RRR-α-
tocopherol in every cell line tested at 72 hours and in
SW480, HCT-116, and HT-29 at 48 hours as demon-
strated by post hoc analyses (Table 1). In the HCT-15
(COX-2 deficient) and SW480 (COX-2 deficient) cell
lines, RRR-α-tocopherol treatment resulted in a statisti-
cally significant increase in cell growth compared with the
vehicle, which was most evident at the 72-hour time inter-
val. RRR-γ-tocopherol treatment resulted in a statistically
significant reduction in proliferation with every cancer
cell line tested. The HT-29 (COX-2 positive) cells demon-
strated a slight resistance to RRR-γ-tocopherol treatment,
initially (24-hour treatment) however, by 48 hours RRR-
γ-tocopherol was as effective in HT-29 cells as in the other
cells treated.
Effects of RRR-α- and RRR-γ-tocopherol treatment on cell 
viability in human colon cancer cell lines compared with 
human normal colon cell line CCD-112CoN
The effects of 100 µM RRR-α- and RRR-γ-tocopherol treat-
ments on cell viability were monitored with hemocytom-
eter cell counts and the use of trypan blue dye following
72 hours in the normal nontransformed colon cell line
CCD-112CoN (Figure 2E). RRR-γ-tocopherol treatment
resulted in no cytotoxicity to normal colon cells, but dem-
onstrated selectivity against cancer cell growth in all four
colon cancer cell lines treated (Figure 2). RRR-α-tocophe-
rol resulted in a statistically significant increase in CCD-
112CoN cells.
Effects of lower RRR-α- and RRR-γ-tocopherol treatment 
concentrations for extended time intervals on human 
colon cancer cell proliferation
Since 100 µM is not a physiologically achievable concen-
tration for dietary RRR-γ-tocopherol, we wanted to deter-
mine if similar results could be obtained with lower
concentrations over longer time intervals. SW480, HCT-
116, and HT-29 cells were treated with 25 µM of either
RRR-γ-tocopherol or RRR-α-tocopherol for 9–10 days.
Figure 3 shows the live cell counts as a function of time for
the SW480 and HT-29 cell lines. RRR-γ-tocopherol treat-
ment in the SW480 cells resulted in significantly less live
cells compared to the vehicle treatment after 96 hours and
time periods beyond 144 hours (p < 0.05). In the SW480
cells, RRR-γ-tocopherol-treated cell numbers were signifi-
cantly less than the RRR-α-tocopherol treated up to 216
hours. In the HT-29 cell line, the RRR-γ-tocopherol treat-
ment is statistically less at time periods longer then 216
hours. The effects of RRR-α-tocopherol, in the HT-29 cells,
are not statistically different from that of vehicle-treated
cells. The HCT-116 cells showed no statistical difference
from the control for either RRR-α-tocopherol or RRR-γ-
tocopherol treatment at any time point tested (data not
shown).
Effects of RRR-α- and RRR-γ-tocopherol treatment on 
apoptosis in human colon cancer cell lines
The effects of RRR-α-tocopherol and RRR-γ-tocopherol on
apoptosis were measured by three independent assays on
two selected colon cancer cell lines SW480 (COX-2 defi-
cient) and HCT-116 (COX-2 inducible). In addition to the
variable COX-2 expression, the SW480 and HCT-116 cell
lines were selected for the apoptosis studies because these
cell lines resulted in significant RRR-α-tocopherol-medi-
ated cell death above the vehicle at 72 hours. It was rea-
soned that if RRR-α-tocopherol could mediate apoptosis;
it would be seen in these two cell lines. First, annexin V/
propidium iodide (PI) double staining was performed
(Figure 4). This method identifies the percentage of cells
that are in early (annexin V positive cells in lower right
quadrant) and late apoptosis (annexin V and PI positive
cells, double stained in the upper right quadrant). Both
cell lines demonstrate significant apoptosis occurring fol-
lowing treatment with RRR-γ-tocopherol, but much less
with the RRR-α-tocopherol treatment. In fact, the SW480
Table 1: Statistical results comparing the trypan blue live-cell means of the tococpherol-treated sampleswith vehicle-treated sample at 
48 and 72 hours following 100 µM tocopherol treatment
SW480 HCT-15 HCT-116 HT-29 CCD-
112CoN
Treatment Agent p-value 48 
hour
p-value 72 
hour
p-value 48 
hour
p-value 72 
hour
p-value 48 
hour
p-value 72 
hour
p-value 48 
hour
p-value 72 
hour
p-value 72 
hour
alpha tocopherol 0.034 <0.001 0.775 <0.0001 0.996 0.084 0.000 <0.0001 0.020
gamma tocopherol 0.0001 <0.001 0.112 <0.0001 0.0005 0.005 <0.0001 <0.0001 0.927
15-deoxy ∆12, 14 PGJ2 0.0004 <0.001 N/A N/A N/A N/A N/A N/A N/A
troglitazone N/A N/A N/A N/A 0.0003 0.0005 0.0000 <0.0001 <0.0001
camptothecin N/A N/A 0.853 <0.001 N/A N/A N/A N/A N/A
alpha vs. gamma <0.018 <0.001 0.416 <0.001 0.0005 0.001 0.0000 <0.0001 0.0117
*Comparison of means was performed using one-way anova and a Tukey's post hoc analysis. Data are representative of three independent trials 
performed in triplicate.BMC Cancer 2006, 6:13 http://www.biomedcentral.com/1471-2407/6/13
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cells treated with RRR-α-tocopherol have no more than
11% of the cells undergoing early and late stage apoptosis
combined. In both cell lines tested the ratio of RRR-γ-
tocopherol-mediated late stage apoptosis is five times that
of RRR-α-tocopherol.
To confirm that apoptosis resulted from tocopherol treat-
ment, a DNA laddering assay was performed (Figure 5).
DNA laddering is only evident in the RRR-γ-tocopherol
treated sample, but not the RRR-α-tocopherol treated
sample in both SW480 and HCT-116 cell lines.
Further, we sought to determine which apoptotic path-
way(s) are involved in the RRR-γ-tocopherol-mediated
apoptosis, by monitoring caspase activation. Western blot
analyses demonstrated that PARP, caspase 3, 7 and 8 are
activated by cleavage in both cell lines with RRR-γ-toco-
pherol treatment, but not RRR-α-tocopherol treatment
(Figure 6). Caspase 9 was not activated by cleavage in
either cell line (data not shown).
Intracellular accumulation of RRR-α- and RRR-γ-
tocopherol treatment is both time and concentration 
dependent
The intracellular accumulation of RRR-α- and RRR-γ-toco-
pherol in SW480 cells was determined as a function of the
tocopherol concentration in the media (Figure 7A) and as
a function of time (Figure 7B). Figure 7A demonstrates
that the uptake of vitamin E is concentration dependent.
We wanted to determine if the cellular up take during our
treatment conditions (100 µM RRR-α- or RRR-γ-tocophe-
rol at 24, 48 and 72 hours) followed a linear time depend-
ent relationship. As shown in Figure 7B, the cellular
uptake of RRR-α- and RRR-γ-tocopherol with respect to
time is linear. The intracellular concentration of the vita-
min E isoforms were normalized to the number of live
cells in the sample at each time point. This was required
since the tocopherols resulted in cell death at 100 µM. The
intracellular concentrations of RRR-α- and RRR-γ-toco-
pherol were very low (femtomoles/cell) when compared
to the amount of tocopherol added to the media (100
µM) but the RRR-γ-tocopherol intracellular uptake was
significantly higher than that of RRR-α-tocopherol.
Discussion
Recently published work has demonstrated disparity
among the vitamin E isoforms, analogs, and metabolites
to induce apoptosis. For example, VES and CEHC metab-
olites of vitamin E are strong apoptotic inducers, while α-
tocopherol acetate (RRR- or all-rac- not specified), α-toco-
pheryl acetate (RRR- or all-rac- not specified) and α-toco-
pherol (RRR- or all-rac- not specified) are weak apoptotic
inducers [17,18,20]. Gysin et al. used 25 µM RRR-γ-, RRR-
α- and RRR-β-tocopherol, compared the proliferation
effects, and determined that RRR-γ-tocopherol was best at
inhibiting cell proliferation in human prostate carcinoma
cells (DU-145 and LNCaP), human colorectal adenocarci-
noma cells (CaCo2), and human osteosarcoma cells
(SaOs-2). In this study, Gysin did not test the colon cancer
cell line for apoptosis. They found no apparent cell death
in the CaCo2 cells when using the trypan blue assay to test
with 25 µM tocopherols. They further tested the DU-145
and LNCaP cell lines for apoptosis at the 25 µM RRR-γ-
tocopherol concentration and found less than 3% of the
cells were apoptotic. When employing 100 µM RRR-γ-
tocopherol treatment to HCT-116 and SW480 cell lines
we found significant apoptosis (Figures 4, 5 and 6). We
Live Cell Counts following a 25 µM α- and γ-tocopherol  treatment at varying times up to ten days in SW480 cells (A)  and HT-29 cells (B) Figure 3
Live Cell Counts following a 25 µM α- and γ-tocopherol 
treatment at varying times up to ten days in SW480 cells (A) 
and HT-29 cells (B). (Data are representative of two inde-
pendent trials performed in triplicate. *p < 0.05 vs. vehicle at 
corresponding concentration).
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suspect the reason for this discrepancy involves the cellu-
lar uptake of RRR-γ-tocopherol. We demonstrated that
uptake of the tocopherols is concentration dependent. We
suspect that the variation in apoptotic induction is due to
the fact that we used a tocopherol concentration that was
four times higher thereby significantly increasing cellular
tocopherol uptake.
A number of studies have demonstrated that RRR-γ-toco-
pherol has chemopreventive properties not shared with
RRR-α-tocopherol. For example, can lower levels of C-
reactive protein [11], inhibit neoplastic transformation
[12], suppress ras p-21 [10], inhibit COX-2 activity [13],
down regulate cyclins [14], and up regulate PPAR γ [22].
Our study is the first to demonstrate that RRR-γ-tocophe-
rol can result in cell death and apoptosis to colon cancer
cell lines, with no significant cytotoxic effects to normal
colon cells.
We acknowledge that 100 µM concentrations of tocophe-
rols used in cell culture experiments is not an achievable
plasma level through oral administration in humans but
could be achieved by other methods such as intravenous
vitamin E-liposomes [24]. The intravenous use of antioxi-
dant liposomes could by-pass the bioselective processes of
the liver and rapidly increase plasma and tissue levels of
RRR-γ-tocopherol beyond what can be achieved by oral
administration. In vivo experiments in a rat model suggest
that colonocytes receive RRR-γ-tocopherol from both
The annexin V/propidium iodide double staining assay following 100 µM tocopherol treatment in HCT-116 cells (Panels A-D)  for 24 hours and SW480 (Panels E-H) cells for 70 hours Figure 4
The annexin V/propidium iodide double staining assay following 100 µM tocopherol treatment in HCT-116 cells (Panels A-D) 
for 24 hours and SW480 (Panels E-H) cells for 70 hours. These data show RRR-γ-tocopherol is superior to RRR-α-tocopherol 
at inducing apoptosis. The percentages in right quadrants represent percentage apoptosis over the blank and are an average of 
at least two independent trials.
23%
32%
camptothecin
15.66%
32.3%
camptothecin
25%
10%
D-tocopherol
5.1%
5.1%
D-tocopherol
16.6%
24.9%
J-tocopherol
42%
10%
J-tocopherol
vehicle
1%
0%
vehicle
1.1%
1.2%
A. B. C. D.
H. G. F. E.
Annexin V 
P
r
o
p
i
d
i
u
m
I
o
d
i
d
e
γ-Tocopherol treatment results in DNA laddering in HCT- 116 cells (Panel A) and SW480 cells (Panel B) following a 100  µM tocopherol treatment for 48 hours (V = vehicle, C =  camptothecin (+) control, A = alpha tocopherol, G = gamma  tocopherol) Figure 5
γ-Tocopherol treatment results in DNA laddering in HCT-
116 cells (Panel A) and SW480 cells (Panel B) following a 100 
µM tocopherol treatment for 48 hours (V = vehicle, C = 
camptothecin (+) control, A = alpha tocopherol, G = gamma 
tocopherol).
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plasma and the contents of the digestive tract [10]. In
humans, consuming a Western diet the dietary levels of
RRR-γ-tocopherol are much higher than that of RRR-α-
tocopherol. It would be expected, therefore, that RRR-γ-
tocopherol would make a significant contribution to the
total tocopherol content of colonocytes. Levels of RRR-γ-
tocopherol in human colonocytes are indeed higher than
that of RRR-α-tocopherol [25]. These data suggest that lev-
els of RRR-γ-tocopherol in colonocytes could be much
higher than reflected by plasma levels where ratio of RRR-
γ-tocopherol to RRR-α-tocopherol is about 1 to 10
[10,25].
Western Blot analysis of SW480 (left) and HCT-116 (right) cell lysates following treatment with 100 µM tocopherols for 24  hours blotted with the antibodies to caspase 3, caspase 7, caspase 8, PARP, and β-actin as a loading control Figure 6
Western Blot analysis of SW480 (left) and HCT-116 (right) cell lysates following treatment with 100 µM tocopherols for 24 
hours blotted with the antibodies to caspase 3, caspase 7, caspase 8, PARP, and β-actin as a loading control.
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Our HPLC results also indicate that at the 100 µM vitamin
E concentrations used to treat these colon cancer cells
only femtomoles of vitamin E are available inside the cell,
yet, at these intracellular concentrations (femtomoles/
cell), cell death and apoptosis were induced. It is a signif-
icant finding that intracellular concentrations in the fem-
tomole range can induce cell death in colon cancer cells.
To date, it is not known whether these intracellular con-
centrations of femtomoles can be achieved in vivo
through dietary means. Further research needs to be per-
formed to determine what physiological intracellular and
tissue concentrations of vitamin E isoforms are achievable
within various tissues. In addition, our HPLC results indi-
cate that the longer the cells are exposed to vitamin E iso-
forms, the higher the intracellular accumulation of
vitamin E. With this in mind, we demonstrated that colon
cancer cell lines exposed to physiological concentrations
of RRR-γ-tocopherol for extended periods of time undergo
reduced cell proliferation. These data suggest that dietary
RRR-γ-tocopherol could have a protective effect over a
long time span through a gradual tissue accumulation
reaching the femtomole/cell range and thereby be chem-
opreventive.
We can only speculate at this time on the molecular basis
for the differences in the growth inhibitory effects on the
different colon cancer cell lines. There are, however, some
interesting data correlations that can be made between the
molecular characteristics of the cell lines and the effects of
the tocopherols in this study. For example, HCT-15 and
SW480 cells are COX-2 negative, HCT-116 cells are COX-
2 inducible and HT-29 cells over express COX-2. The
growth inhibitory effect of RRR-α-tocopherol is more pro-
nounced in cells that over express COX-2 (HT-29 cells).
Preliminary work in our laboratories indicate that toco-
pherols suppress COX-2 in HT-29 and CaCo2 cells
(unpublished) and it is possible that some of the apop-
totic effects of tocopherols are mediated by COX-2 sup-
pression and hence are more apparent in cells that express
COX-2. The HT-29 cells are slightly more resistant to cell
death than the other cell lines as demonstrated by the
increase in cell number over the vehicle at 24 hours. This
may be due to the COX-2 expression in HT-29 cells. It is
known that the expression of COX-2 can mediate apop-
totic resistance in cancer cells [26]. Further investigation is
underway in our laboratories to explore if the effects of
RRR-α- and RRR-γ-tocopherol on COX-2 expression and
apoptosis in these cell lines. Jiang et al. have demonstrated
that RRR-γ-tocopherol, but not RRR-α-tocopherol
decreases the activity of COX-2 in IL-1 and LPS-stimulated
macrophages. Jiang et al. also demonstrated that, in mac-
rophages, neither COX-2 protein or mRNA expression
was affected by tocopherol treatment, leading to the spec-
ulation that RRR-γ-tocopherol may compete for the ara-
chidonic acid binding site which leads to protein
inhibition and reduced activity [13]. Additionally, SW480
and HT-29 cells have a truncated APC gene, while the
HCT-116 cells have a wild type APC gene. The APC pro-
tein is involved in the regulation of β-catenin. In cancer,
mutations in the APC gene allow for accumulation of β-
catenin. β-Catenin is a nuclear transcription factor that
modulates genes associated with cell proliferation. Accu-
mulation of β-catenin protein leads to enhanced cell pro-
liferation by dysregulation of the wnt pathway [27]. Our
data show that HCT-116 cells are not affected by 25 µM
tocopherol treatment at any time point tested (maximum
10 days), while the SW480 and HT-29 cell lines show a
reduction in cell proliferation, indicating that RRR-γ-toco-
pherol may have an effect on cell proliferation by regula-
Cellular up take of RRR-α- and RRR-γ-tocopherol is time and  concentration dependent, with RRR-γ-tocopherol accumulat- ing to a higher intracellular concentration Figure 7
Cellular up take of RRR-α- and RRR-γ-tocopherol is time and 
concentration dependent, with RRR-γ-tocopherol accumulat-
ing to a higher intracellular concentration. A) SW480 cells 
were treated with varying concentrations of RRR-α- and 
RRR-γ-tocopherol for 24 hours. B) SW480 cells were 
treated with 100 µM RRR-α- or RRR-γ-tocopherol, col-
lected, counted and subjected to HPLC analysis after 24, 48 
and 72 hour treatments. Values are average of three inde-
pendent experiments and error bars represent standard 
deviation. Time-dependent HPLC values were normalized to 
cell counts due to cell death at longer time intervals.BMC Cancer 2006, 6:13 http://www.biomedcentral.com/1471-2407/6/13
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tion of the wnt pathway. It is well documented that
disruption of the wnt pathway occurs early in the carcino-
genesis process. The potential modulation of the wnt
pathway by RRR-γ-tocopherol needs to be investigated
further.
Jiang et al. has performed mechanistic studies suggesting
that RRR-γ-tocopherol induces prostate cancer cell death
by disrupting the de novo sphingolipid pathway which is
important for the biosynthesis of ceramide [28]. Cera-
mide has received considerable attention as a potential
second messenger important for inducing apoptosis [29-
31]. In the sphingolipid study, vitamin E did not show an
apoptotic effect on LNCaP prostate cells until 72 hours
following treatment. The apoptotic event correlated with
the increase and accumulation of dihydroceramide and
dihydrosphingosine. Our data demonstrates a similar
time differential before apoptosis occurs in the colon can-
cer cell lines we tested. It is possible that RRR-γ-tocopherol
may interfere with the de novo sphingolipid pathway in
the colon cells as well as prostate cells to induce apoptosis
by production of ceramide. There are different compart-
mentalized pathways of ceramide signaling, each having
unique molecular signatures for apoptosis/proapoptosis
[32]. For example, lysosomal ceramide generation results
in Cathespin D and BID-mediated activation of caspase 9
and 3. The generation of ceramide in the ER or mitochon-
dria will cause protein phosphatase 1-mediated activation
of caspase 9. Ceramide generation in the lipid membrane
can affect signaling pathways generated by receptors such
as Fas resulting in the activation of caspase 8. Our data dif-
fers from that of Jiang et al. with respect to caspase 9 cleav-
age. We did not observe caspase 9 cleavage in the colon
cells whereas Jiang et al. observed caspase 9 cleavage in the
prostate cells. This means that if vitamin E is following a
pathway involving ceramide biosynthesis, the cellular
sublocalization of vitamin E mediation of ceramide is dif-
ferent in colon from that of the prostate gland. It is likely
that if RRR-γ-tocopherol interacts to interfere with sphin-
golipid synthesis in the colon it happens in the plasma
membrane as we have detected cleavage of caspase 8. This
pathway requires further investigation in the colon.
Our research group previously found that RRR-γ-tocophe-
rol up regulates the expression of peroxisome proliferator
activator receptor-gamma (PPAR-γ) more effectively than
RRR-α-tocopherol [22]. PPAR γ is a key molecular target
for cancer chemoprevention. Many in vitro and xenograft
studies have demonstrated that PPAR γ ligands are anti-
tumorigenic due to anti-proliferative, pro-differentiation
and anti-angiogenic effects [33-38]. RRR-γ-tocopherol
mediated cell death and apoptosis may follow a PPAR γ
dependent mechanism in HCT-116, SW480 and HT-29
cell lines, but not in HCT-15 cells which have a point
mutation (K422Q) and express a mutant form of PPAR γ.
This mutation makes them resistant to ligand activation.
Our data (Figure 2) shows that RRR-γ-tocopherol induces
cell death in the HCT-15 cells, therefore we suspect that
the RRR-γ-tocopherol mediated cell death does not occur
through a PPAR γ dependent mechanism only but that
other pathways are involved. It is possible that vitamin E
may activate multiple pathways in concert resulting in
apoptosis and cell death of colon cancer cells of different
prosurvival factors result in the variations among cell lines
to induce apoptosis (as in the 24-hour data obtained with
the HT-29 cell line). The potential pathways of tocopherol
activity under investigation in our laboratories include
mechanisms related to lipid metabolism (COX-2, lipoxy-
genase, and sphingolipid pathways) and to pathways not
related to lipid metabolism (wnt pathway).
Conclusion
The effectiveness of γ-tocopherol to inhibit cell prolifera-
tion in these human colon cell lines vary according the
individual molecular characteristics of each line. This
study indicates that RRR-γ-tocopherol mediated apoptosis
in colon cells largely follows a death receptor pathway
since caspase 8, but not caspase 9 cleavage was detected.
This study demonstrates that both physiological (25 µM)
and pharmacological concentrations (100 µM) of RRR-γ-
tocopherol effectively reduced cell proliferation in malig-
nant colon cancer cell lines that possess different molecu-
lar signatures without damage to normal colon cells.
Based on our studies, it is possible that both physiological
and pharmacological concentrations of RRR-γ-tocopherol
may have a role in the prevention and therapy of colorec-
tal cancer. Physiological concentrations of RRR-γ-toco-
pherol as taken in the diet may be chemopreventive, while
pharmacological concentrations of RRR-γ-tocopherol may
be used in conjunction with chemotherapeutic agents as
adjunctive therapy enabling the reduction in the concen-
trations of toxic chemotherapeutic agents, maintaining
the levels of cell cancer cell death while reducing the death
of normal colon cells.
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